Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

Heart disease risk factors widespread among Hispanic/Latino adults in the U.S.

Hispanic Community Health Study/Study of Latinos (HCHS-SOL) - which will be presented at the American Heart Association Annual Meeting in Los Angeles on Nov. 5 and published in the Nov. 7 issue of the Journal of the American Medical Association (JAMA) - finds heart disease risk factors are widespread among Hispanic/Latino adults in the United States.

7 Nov 2012

Treatment with AMG 145 reduces LDL cholesterol

Amgen today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.

7 Nov 2012

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Santarus, Inc. and Pharming Group NV today announced that their pivotal Phase III clinical study to evaluate the safety and efficacy of the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met the primary endpoint of time to beginning of symptom relief.

7 Nov 2012

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today presented key findings related to lipoprotein particles (LDL-P) and cardiovascular disease at the Annual Meeting of the American Heart Association (AHA) in Los Angeles.

7 Nov 2012

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Monoclonal antibody boosts cholesterol reduction

Adding a monoclonal antibody that blocks the breakdown of lipid receptors to atorvastatin therapy further reduces low-density lipoprotein cholesterol levels in patients with primary hypercholesterolemia, show study findings.

6 Nov 2012

New test device allows 'more real-life modeling' of contact lens wear

Modern contact lens materials are prone to drying when exposed to air, which contributes to the buildup of deposits on contact lenses, according to a study - "The Impact of Intermittent Air Exposure on Lipid Deposition", appearing in the November issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

6 Nov 2012

Probiotic formulation can reduce cholesterol esters

Two daily doses of a probiotic lowered key cholesterol-bearing molecules in the blood as well as "bad" and total cholesterol, in a study presented at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Gene silencing technology used to fight RSV and influenza

New hope has arrived for the fight against two deadly viral infections, RSV and influenza, as Griffith researchers prepare to develop a cutting-edge approach to treatment delivery.

6 Nov 2012

Peptide-enhanced tomatoes reduce atherosclerosis in mice

For the first time, genetically engineered tomato plants produced a peptide that mimics the actions of good cholesterol when eaten, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Patients with diabetes, multi-vessel coronary artery disease can benefit from bypass surgery

An international, clinical research trial has shown that patients with diabetes whose multi-vessel coronary artery disease is treated with bypass surgery live longer and are less likely to suffer severe complications like heart attacks than those who undergo angioplasty.

6 Nov 2012

Lifetime risks for total CVD are high regardless of index age

Even in men and women with an optimal cardiovascular disease (CVD) risk factor profile, the lifetime risk estimate for CVD is greater than 30 percent, and is more than 50 percent for men and women overall, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

6 Nov 2012

Latinos, Hispanics in the U.S. more likely to develop major cardiovascular diseases

Hispanics and Latinos living in the U.S. are highly likely to have several major cardiovascular disease risk factors, such as high cholesterol, high blood pressure, obesity, diabetes, and smoking, according to a new, large-scale study. Risks vary among the diverse Hispanic/Latino groups, but individuals who were born in the U.S. are more likely to have multiple risk factors.

6 Nov 2012

Keeping cardiovascular disease risk factors low may lead to a longer, healthier life

If you have optimal heart health in middle age, you may live up to 14 years longer, free of cardiovascular disease, than your peers who have two or more cardiovascular disease (CVD) risk factors, according to a new Northwestern Medicine study.

6 Nov 2012

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

An intravenous infusion of good cholesterol could reduce the risk of a subsequent heart attack, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Study: Many Hispanic/Latino adults in the U.S. are at high risk for heart attack or stroke

A study published today in the Journal of the American Medical Association (JAMA) indicated that many Hispanic/Latino adults living in the United States are at high risk for heart attack or stroke. This risk is highest in men and in older people, born in the US or that have lived in the US more than 10 years, that prefer to speak English, are lower income, or never finished high school.

5 Nov 2012

Study compares effectiveness of CABG surgery with PCI for adults with diabetes and heart disease

Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

5 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Cholesterol News and Research

Further Reading

Heart disease risk factors widespread among Hispanic/Latino adults in the U.S.

Treatment with AMG 145 reduces LDL cholesterol

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Monoclonal antibody boosts cholesterol reduction

New test device allows 'more real-life modeling' of contact lens wear

Probiotic formulation can reduce cholesterol esters

Gene silencing technology used to fight RSV and influenza

Peptide-enhanced tomatoes reduce atherosclerosis in mice

Patients with diabetes, multi-vessel coronary artery disease can benefit from bypass surgery

Lifetime risks for total CVD are high regardless of index age

Latinos, Hispanics in the U.S. more likely to develop major cardiovascular diseases

Keeping cardiovascular disease risk factors low may lead to a longer, healthier life

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

Study: Many Hispanic/Latino adults in the U.S. are at high risk for heart attack or stroke

Study compares effectiveness of CABG surgery with PCI for adults with diabetes and heart disease

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News